report (Pintor et al, 1990) . The editor of the Nev Englcand Jolunal of Medicine at the time wrote an editorial to accompany that retraction entitled 'An error corrected, a conclusion withdrawn, and a lesson learned ' (Relman, 1990) . Unfortunately, this artifactprone assay remains in wide use. While many data exist in support of a role for the IGF system in the pathogenesis of prostate cancer, it is the autocrine-paracrine involvement of IGFs and IGFBPs that is commonly implicated, as reviewed by Peehl et al (1996) . However, measurements of IGF-1 in two previous studies using valid methodologies (Cohen et al, 1993; Ho and Baxter, 1997) , demonstrated normal serum levels, indicating that there is no relationship between circulating IGF-I levels and the prevalence of prostate cancer. We would therefore like to encourage Mantzoros et al (1997) to re-assay their patients' sera in an IGF-I assay, which can be demonstrated to be free of IGFBP interference; otherwise, their conclusions may not be valid. Insulin-like growth factor I in relation to prostate cancer and benign prostatic hyperplasia -reply to the letter from Cohen, Peehl and Rosenfeld Sir, We thank Dr Cohen and colleagues for their interest in our paper.
They may or may not be correct in their assertion that the laboratory procedure that we have used to measure insulin-like growth factor I (IGF-1) has reduced specificity, notwithstanding the manufacturers' claim of no interference. What they fail to realize, however, is that their own study (Cohen et al, 1993 ) is actually suggestive of a positive association between IGF-I and prostate cancer. Indeed, had their study been as large as ours (51 cases and 52 controls), the difference between mean IGF-I levels of their cases and controls would have been marginally significant (P = 0.06). They have also made a mistake in their indication of the 'standard error' of the mean IGF-1 value, when, in reality, this must have been the standard deviation -otherwise the standard deviation of IGF-1 among their cases would have been much higher than their mean value! There is a lesson here: lack of statistical significance is frequently due to limited statistical power and should never be the basis for a confident assertion of no association. The other study that Cohen and colleagues refer to (Ho and Baxter, 1997) is even smaller than their own, with only seven controls.
Cohen and colleagues' claim also implies that a qualitatively similar phenomenon would create an artificial positive association between IGF-1 and benign prostatic hyperplasia (BPH), even though in our study there was absolutely no relationship between IGF-1 and BPH after adjusting for confounding variables (Table 4 in Mantzoros et al, 1997). If they are still worried, however, they could also look to the findings of a new study recently published in Science (Chan et al, 1998) . Using a different assay, this study has confirmed our findings almost to the decimal point. 1992; Hill, 1993; Altman et al, 1994 Altman et al, , 1995 . Regrettably, this method, which is better referred to as the minimum P-value method, continues to appear in papers published in the British Journal of Cancer. Briefly, the minimum P-value method is as follows:
(1) each distinct observed value of the marker is taken in turn as a cutpoint and two groups of patients created with values below or above this level (a variation is to use equi-spaced values across the observed range); (2) for each such grouping a log-rank test is performed and the P-value determined; (3) the cutpoint with the lowest P-value is called 'optimal', Kaplan-Meier curves are constructed for groups created with this cutpoint and the P-value reported; (4) in most cases the resulting binary variable is included with other variables in a Cox multiple regression analysis.
The dangers of this approach have been outlined (Altman et al, 1994) and include:
(a) because of multiple testing the false-positive rate is around 40% rather than the nominal 5%; (b) the P-value is far too small (P = 0.002 corresponds to a genuine P = 0.05); (c) the value of the cutpoint has no clinical meaning; (d) the analysis gives no information about the shape of the relation between the level of the tumour marker and prognosis.
In addition, when step (4) above is followed, the bias from the univariate analysis is transferred to the multivariate setting (Altman et al, 1994) . It is not surprising, therefore, that such analyses often show that the tumour marker is apparently more important (i.e. has a smaller P-value) than other variables in univariate analyses, and that they usually retain significance after adjustment for standard risk factors. These problems arise from the search for the 'best' result. The consequence is a cutpoint that may be best in the narrow sense described, but which will not offer a true indication of the importance of the tumour marker.
Looking quickly through a few recent issues of the journal I found three such studies. Dettmar et al (1997) studied the prognostic relevance of MIBl (Ki-67) and S-phase fraction (SPF) for disease-free survival in node-negative breast cancer. The authors followed steps (1) to (4) above and reported P-values of 0.0224 and 0.0028, respectively, for the two markers. When adjustment is made for multiple testing (Altman et al, 1994) , the corrected Pvalues are unimpressive, being 0.29 and 0.06. The authors performed Cox regression analysis using the two binary marker indicators as well as established prognostic factors (none of which was significant in univariate analyses). They report that SPF was the only significant variable in the Cox analysis and that it was (therefore) the strongest prognostic factor. Buer et al (1997) studied the relation of serum levels of S100 and survival in metastatic malignant melanoma. These authors also followed steps (1) to (4). The P-value for the optimal cutpoint was reported as P < 0.001, which converts to P < 0.025 after adjustment. S100 was not found to retain its prognostic value in a Cox analysis. Gustafson et al (1997) probably also followed the four steps above, although they do not state explicitly that they minimized the P-value. These authors examined multiple cutpoints in the study of SPF in soft-tissue sarcoma. SPF retained its significance in the multivariate model, ahead of other variables, including grade of malignancy.
It is worrying that many authors, not only in this journal, continue to use this dubious methodology, especially after its deficiencies have been highlighted several times. Calling the method 'optimal' attaches an unwarranted and inappropriate cachet to a highly suboptimal strategy. Dozens of papers have used this dubious method, including, I am sure, many that have not declared it (as many papers do not explain their choice of cutpoint; Altman et al, 1995) . No authors have cited a statistical text or paper to support the method, of which I believe there is none, although some authors have investigated ways to improve the procedure (Faraggi and Simon, 1996; Hilsenbeck and Clark, 1996) . While misleading results from individual studies are undesirable, they may also distort the results of a subsequent metaanalysis. Ferrandina et al (1997) recently described a meta-analysis of 11 studies that examined the relation between cathepsin D and disease-free survival in breast cancer. They reported that authors had used cutpoints in the range 24-78 pmol mg-'. They noted that interstudy heterogeneity in the relative risk was 'remarkably high'. Some of the heterogeneity is likely to be due to the use of the minimum P-value method in some studies. The authors of the meta-analysis commented on this possibility, but did not compare results according to the method of deriving the cutpoint. Indeed, one of the studies included by Ferrandina et al found a significant cutpoint using exploratory multiple cutpoint analyses, but the authors concluded from further analyses that this finding was unsound (Ravdin et al, 1994) . It would be helpful to have results of such meta-analyses related to the method of selection of the cutpoint or, better still, based on the raw data without the use of cutpoints.
